search
Back to results

Study Comparing PEG 3350 Laxative to Placebo in the Treatment of Occasional Constipation (Study CL2007-12)(P08216)

Primary Purpose

Constipation

Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Polyethylene glycol 3350
Placebo, maltodextrin 500 powder for solution
Sponsored by
Bayer
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Constipation focused on measuring Human Experimentation

Eligibility Criteria

17 Years - undefined (Child, Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Subjects (or parents/guardians of minors) must demonstrate their willingness to participate (or to have their children/wards participate) in the study and comply with its procedures by signing a written informed consent. Minor subjects must provide written assent.
  • Subjects must be 17 years of age or older.
  • Subjects must present with a current diagnosis of untreated constipation for 7 days or less based on having signs/symptoms of straining and hard or lumpy stools OR the inability to have a BM within 48 hours prior to randomization into the trial.
  • Subjects must be OTC laxative users for the treatment of occasional constipation (defined as using a nonprescription laxative to treat at least 3 episodes of constipation within the last 12 months prior to randomization).
  • Subjects must be willing to use study drug for up to 7 days as directed, and must agree to record bowel movement (frequency, consistency, etc.) accurately and consistently in a daily diary, and make two clinic visits.
  • Subjects must be otherwise in good health, as determined by physical exam and medical history.
  • Subjects must agree not to use any other products to treat their constipation during the course of the study.
  • Subjects must agree not to use any medication known to cause constipation during the course of the study.
  • Subjects must agree to maintain a similar diet from the week prior to randomization through end of study.
  • Female subjects must be either surgically sterile, 2 years post-menopausal, or they attest that they are using an acceptable method of contraception (including hormonal birth control, IUD, double barrier methods, or vasectomized partner). In females of childbearing potential, the urine pregnancy test (HCG) must be negative at Baseline.
  • Subjects must be able to read the diaries in English.

Exclusion Criteria:

  • Subjects currently under a doctor's care and treatment for constipation.
  • Subjects having current constipation episode for more than one week prior to randomization.
  • Subjects that have a history of chronic constipation due to any underlying cause (inflammatory bowel disease, etc.).
  • Subjects have a history of more than 3 months of constipation in the past year.
  • Subjects have severe abdominal pain as the predominant constipation symptom.
  • Subjects who have previously used a polyethylene glycol laxative.
  • Subjects who have celiac disease or known gluten sensitivity.
  • Subjects who have a history of colorectal cancer, anal abscess, anal fistula, anal fissure, anal stenosis, gastric retention or obstruction, bowel resection, rectocele, or colostomy.
  • Subjects with known renal or hepatic insufficiency.
  • Subjects with gastrointestinal bleeding or acute infection.
  • Subjects with a history of alcohol or drug abuse.
  • Subjects with a history of psychiatric disorders.
  • Subjects with a history of significant ongoing medical problems, including kidney disease, or who are scheduled for surgical procedures.
  • Subjects currently taking or taken within 7 days of randomization a concomitant medication that causes constipation including for example opiates, antidepressants, SSRI's, antimotility agents, and anticholinergics, etc.
  • Subjects who plan to use laxatives during the treatment period other than the study medication.
  • Subjects who, in the opinion of the investigator, should not be included in the study for any reason, including inability to follow study procedures.
  • Subjects who have participated in an investigational clinical surgical, drug or device study within the past 30 days.
  • Subjects who are pregnant or lactating.
  • Subjects who are allergic to polyethylene glycol or maltodextrin.
  • Subjects who are employed or have immediate family members employed by a company that manufactures laxative products.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Placebo Comparator

    Arm Label

    Polyethylene glycol 3350 powder for solution

    Placebo

    Arm Description

    MiraLAX® (polyethylene glycol 3350 powder for solution)

    MALTRIN 500® M500 (maltodextrin 500)

    Outcomes

    Primary Outcome Measures

    Number of Participants With a Complete Resolution at the Final Visit
    A resolution was recorded if the participant has no occurrence of two or more consecutive unsuccessful bowel movements for the rest of the study following the first successful bowel movement.

    Secondary Outcome Measures

    Full Information

    First Posted
    October 9, 2008
    Last Updated
    September 4, 2018
    Sponsor
    Bayer
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00770432
    Brief Title
    Study Comparing PEG 3350 Laxative to Placebo in the Treatment of Occasional Constipation (Study CL2007-12)(P08216)
    Official Title
    A Randomized, Placebo-Controlled, Double-Blind, Trial of Polyethylene Glycol 3350 Laxative for the Treatment of Occasional Constipation.
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    September 2018
    Overall Recruitment Status
    Completed
    Study Start Date
    November 2007 (undefined)
    Primary Completion Date
    January 2008 (Actual)
    Study Completion Date
    January 2008 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Bayer

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Randomized, placebo-controlled, double blind study. 203 subjects entered the study to compare the effect on occasional constipation of polyethylene glycol 3350 to placebo. Subjects took one of study treatments up to 7 days.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Constipation
    Keywords
    Human Experimentation

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantInvestigator
    Allocation
    Randomized
    Enrollment
    203 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Polyethylene glycol 3350 powder for solution
    Arm Type
    Active Comparator
    Arm Description
    MiraLAX® (polyethylene glycol 3350 powder for solution)
    Arm Title
    Placebo
    Arm Type
    Placebo Comparator
    Arm Description
    MALTRIN 500® M500 (maltodextrin 500)
    Intervention Type
    Drug
    Intervention Name(s)
    Polyethylene glycol 3350
    Other Intervention Name(s)
    MiraLAX®
    Intervention Description
    Polyethylene glycol 3350 powder for solution. Single dose (17 grams in 4 to 8 ounces of beverage) for 7 days.
    Intervention Type
    Other
    Intervention Name(s)
    Placebo, maltodextrin 500 powder for solution
    Other Intervention Name(s)
    MALTRIN® 500 powder for solution
    Intervention Description
    Maltodextrin 500 powder for solution, One single dose (one capful) in any 4 - 8 ounces beverage for 7 days.
    Primary Outcome Measure Information:
    Title
    Number of Participants With a Complete Resolution at the Final Visit
    Description
    A resolution was recorded if the participant has no occurrence of two or more consecutive unsuccessful bowel movements for the rest of the study following the first successful bowel movement.
    Time Frame
    24 hours to 3 days after last dose of seven day treatment period.

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    17 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Subjects (or parents/guardians of minors) must demonstrate their willingness to participate (or to have their children/wards participate) in the study and comply with its procedures by signing a written informed consent. Minor subjects must provide written assent. Subjects must be 17 years of age or older. Subjects must present with a current diagnosis of untreated constipation for 7 days or less based on having signs/symptoms of straining and hard or lumpy stools OR the inability to have a BM within 48 hours prior to randomization into the trial. Subjects must be OTC laxative users for the treatment of occasional constipation (defined as using a nonprescription laxative to treat at least 3 episodes of constipation within the last 12 months prior to randomization). Subjects must be willing to use study drug for up to 7 days as directed, and must agree to record bowel movement (frequency, consistency, etc.) accurately and consistently in a daily diary, and make two clinic visits. Subjects must be otherwise in good health, as determined by physical exam and medical history. Subjects must agree not to use any other products to treat their constipation during the course of the study. Subjects must agree not to use any medication known to cause constipation during the course of the study. Subjects must agree to maintain a similar diet from the week prior to randomization through end of study. Female subjects must be either surgically sterile, 2 years post-menopausal, or they attest that they are using an acceptable method of contraception (including hormonal birth control, IUD, double barrier methods, or vasectomized partner). In females of childbearing potential, the urine pregnancy test (HCG) must be negative at Baseline. Subjects must be able to read the diaries in English. Exclusion Criteria: Subjects currently under a doctor's care and treatment for constipation. Subjects having current constipation episode for more than one week prior to randomization. Subjects that have a history of chronic constipation due to any underlying cause (inflammatory bowel disease, etc.). Subjects have a history of more than 3 months of constipation in the past year. Subjects have severe abdominal pain as the predominant constipation symptom. Subjects who have previously used a polyethylene glycol laxative. Subjects who have celiac disease or known gluten sensitivity. Subjects who have a history of colorectal cancer, anal abscess, anal fistula, anal fissure, anal stenosis, gastric retention or obstruction, bowel resection, rectocele, or colostomy. Subjects with known renal or hepatic insufficiency. Subjects with gastrointestinal bleeding or acute infection. Subjects with a history of alcohol or drug abuse. Subjects with a history of psychiatric disorders. Subjects with a history of significant ongoing medical problems, including kidney disease, or who are scheduled for surgical procedures. Subjects currently taking or taken within 7 days of randomization a concomitant medication that causes constipation including for example opiates, antidepressants, SSRI's, antimotility agents, and anticholinergics, etc. Subjects who plan to use laxatives during the treatment period other than the study medication. Subjects who, in the opinion of the investigator, should not be included in the study for any reason, including inability to follow study procedures. Subjects who have participated in an investigational clinical surgical, drug or device study within the past 30 days. Subjects who are pregnant or lactating. Subjects who are allergic to polyethylene glycol or maltodextrin. Subjects who are employed or have immediate family members employed by a company that manufactures laxative products.

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    27158544
    Citation
    McGraw T. Polyethylene glycol 3350 in occasional constipation: A one-week, randomized, placebo-controlled, double-blind trial. World J Gastrointest Pharmacol Ther. 2016 May 6;7(2):274-82. doi: 10.4292/wjgpt.v7.i2.274.
    Results Reference
    derived

    Learn more about this trial

    Study Comparing PEG 3350 Laxative to Placebo in the Treatment of Occasional Constipation (Study CL2007-12)(P08216)

    We'll reach out to this number within 24 hrs